While the CHMP's recommendation for Novartis' Fabhalta1 is a direct boon for Novartis, it indirectly affects VGK by showcasing the innovative capabilities and regulatory successes of European healthcare companies. However, the impact on VGK is less direct and more diffuse, affecting perceptions rather than financial metrics directly.

The recommendation from CHMP for marketing authorization of Fabhalta1 directly impacts Novartis by potentially increasing its market share and revenue in the healthcare sector, specifically in the treatment of Paroxysmal Nocturnal Haemoglobinuria. This positive development is likely to be viewed favorably by investors and could lead to an increase in stock price in the short term.